Top 10 Cancer Screening Recommendations for Average-Risk Adults
Based on the most recent American Cancer Society guidelines, here are the 10 essential cancer screening recommendations prioritizing mortality reduction and quality of life:
1. Breast Cancer Screening
Women should begin annual mammography at age 40 and continue through age 74 1. Between ages 20-39, clinical breast examination (CBE) should be performed every 3 years, then annually after age 40 1. The most recent USPSTF 2024 guidelines recommend biennial (every 2 years) mammography from ages 40-74 2, though ACS maintains annual screening provides greater mortality benefit.
2. Cervical Cancer Screening - Ages 21-29
Begin screening at age 21 with cytology (Pap test) alone every 3 years 3. Do NOT screen women under age 21 regardless of sexual activity, and do NOT use HPV testing in this age group 3.
3. Cervical Cancer Screening - Ages 30-65
The preferred approach is co-testing with HPV and cytology every 5 years 3, 4. Alternatively, cytology alone every 3 years remains acceptable. Primary HPV testing alone every 5 years is now FDA-approved and recommended by USPSTF as an option 4.
4. Cervical Cancer Screening - Stopping Age
Discontinue screening after age 65 if the woman has had 3 consecutive negative cytology tests OR 2 consecutive negative co-tests within the past 10 years, with the most recent test within 5 years 3.
5. Colorectal Cancer Screening - Starting Age 50
Begin screening at age 50 with one of these options 3:
- Colonoscopy every 10 years (most comprehensive)
- High-sensitivity FIT or gFOBT annually
- Flexible sigmoidoscopy every 5 years
- CT colonography every 5 years
- Double-contrast barium enema every 5 years
Annual stool blood testing combined with flexible sigmoidoscopy every 5 years is also acceptable 3.
6. Colorectal Cancer Screening - High-Risk Individuals
For those with first-degree relatives with colorectal cancer or advanced adenomas diagnosed before age 60, begin screening at age 40 5. Use colonoscopy every 5-10 years depending on family history severity 5.
7. Lung Cancer Screening
Annual low-dose helical CT (LDCT) for current or former smokers (quit within past 15 years) ages 55-74 with at least 30 pack-year smoking history and in good health 1, 3. This represents high-risk screening, not average-risk population screening.
8. Endometrial Cancer Counseling
At menopause, inform all women about endometrial cancer risks and symptoms, emphasizing the importance of reporting any unexpected bleeding or spotting immediately 1, 3. This is counseling, not active screening, as no screening test is recommended for average-risk women.
9. Prostate Cancer Shared Decision-Making
Beginning at age 50, offer annual PSA testing and digital rectal examination to men with at least 10-year life expectancy, but only after informed discussion of benefits and harms 1. High-risk men (African descent or first-degree relative diagnosed before age 65) should begin discussions at age 45 6.
10. HPV Vaccination
Routine HPV vaccination for females ages 11-12 years, with catch-up vaccination for ages 13-18 3. This is primary prevention that reduces future cervical cancer incidence, complementing but not replacing screening.
Critical Caveats
Never screen annually for cervical cancer by any method - this increases harms without additional benefit 3.
Single-panel FOBT during digital rectal exam is inadequate for colorectal cancer screening due to very low sensitivity 3.
Breast self-examination (BSE) is optional - women should be counseled about benefits and limitations, with emphasis on prompt reporting of any breast changes 1, 3.
Women who have had total hysterectomy for benign disease do not need cervical cancer screening unless they have history of CIN2 or higher 3, 4.
Dense breast notification laws exist in many states, but evidence remains insufficient to recommend routine supplemental screening with ultrasound or MRI for dense breasts alone 2.
These recommendations apply to average-risk, asymptomatic adults. More intensive surveillance is required for individuals with personal or strong family history of cancer, genetic syndromes, inflammatory bowel disease, or immunocompromised states 3.